5/26/2018 06. Bab v - Lampiran
1/34
BAB V
PENUTUP
A. Kesimpulan
Berdasarkan data yang dikumpulkan dan analisis serta pembahasan yang
dilakukan, maka dapat disimpulkan sebagai berikut:
1. Golongan antipsikotik yang paling besar digunakan pada tahun 2010
berdasarkan perhitungan DDD dalamATC adalah Risperidon dengan persen
penggunaan 47,20 dan Golongan antipsikotik yang paling besar digunakan
pada tahun 2011 berdasarkan perhitungan DDD dalam ATC adalah
Risperidon dengan persen penggunaan 51,5.
!ara pemberian yang dilakukan dengan oral dan parenteral.
Bentuk sediaan yang diberikan tablet dan in"eksi
2. #bat$obat yang masukDU 90% diurut berdasarkan besar penggunaan yaitu%
&ahun 2010 : Risperidon, &ri'luopera(in, )aloperidol.
&ahun 2011 : Risperidon, &ri'luopera(in, )aloperidol.
*. #bat yang digunakan di dalam penelitian ini sudah sesuai dengan
+ormularium Rumah akit tahun 2011.
B. Saran
1. Bagi Rumah akit -ia /aerah urakarta
epada pihak rumah sakit disarankan untuk meningkatkan pelayanan
medik terutama dalam pengobatan terhadap pasien ski(o'renia dengan tetap
52
5/26/2018 06. Bab v - Lampiran
2/34
5*
memantau e'ek samping obat antipsikotik yaitu sindrom parkinson, terutama
untuk obat$obat baru, pasien yang baru mendapat pengobatan serta pada pasien
yang akan menghentikan pengobatan.
2. Bagi peneliti selan"utnya
/iharapkan bagi peneliti selan"utnya untuk melakukan penelitian seara
analisa kualitati' pada penelitian penggunaan antipsikotik agar semakin
berkembangnya in'ormasi$in'ormasi yang menakup tentang antipsikotik.
5/26/2018 06. Bab v - Lampiran
3/34
DAFTAR PUSTAKA
Buku tandar elayanan 3edis edokteran -ia Reisi , 2010, tandarelayanan sikiatrik Rumah akit -ia /aerah urakarta, Gangguan
Mental Dan Priaku, struktur Klasifikasi Gangguan Jiwa Dan Prilaku
Birkett, /.-., 2002, The Future of ATCDDD an! Drug Utili"ation #esea$h. 6)#
/rug n'ormation ol.1 no.*.
British 3edial ssoiation, 2004, ritish &ational For'ular( )*, Royal
harmaeutial oiety o' Great Britain, Germany
!rismon, 3.8., /orson, .G., 2002, hi(ophrenia, /ipiro, -.&.,&albert, R.8., 3at
9he,G.R., ee,G.! and 6ells, 8.3.,Phar'a$othera+i ;athophysiologipproah$1241. 3 Gra$)ill,ne, ?e ork.
/epertemen kesesehatan. 200@. nfor'atoriu' -.at &asional n!onesia/ Badan
#3 R.
/epkes R, edoman engolongan dan /iagnosa Gangguan -ia edisi , tahun
1>>, Diagnosis Gangguan Jiwa halaman 4, enerbit /irektorat
esehatan -ia /irektorat -enderal elayanan 3edik, Rusdi 3aslim.
/epkes R 200>, # ndonesia Aolume 44. -akarta: katan ar"ana +armasi
ndonesia.
+atemi, .)., +olsom, &./., 200>, The &euro!eelo+'ental 1(+othesis of2$hi"o+hrenia, Reisited, hi(ophrenia Bulletin ol.*5no.*pp.52@
54@,200>,http:CCs h i( op h re ni a bull e tin.o D ' o r d"ou r n a ls.o r g C ont e ntC*5C*C52@.
' ull.pd ' ,diakses tanggal 1 -uni 2012.
+E, 2007,Far'akologi !an Tera+i edisi 5, -akarta : /epartemen edokteran
Eniersitas ndonesia.
+ormularium Rumah akit -ia /aerah urakarta halaman 15 =disi &ahun 2011.
mron R.2011, Gangguan Jiwa, httpCimron4html.blogspot, di akses tanggal 25?oember 2011
+, 200@, 2- Far'akotera+i, halaman 2@@$2@>, enerbit & + enerbitan
-akarta.
8aksman, &.). 200*,Ka'us Ke!okteran, enerbit /"ambatan
8indner, 8.3., 3arasiulo, .!., +arias, 3.R., Grohs, G.=.3., 200>,3$ono'i$
ealuation of anti+s($hoti$ !rugs for s$hi"o+hrenia treat'ent within the
ra"ilian 1ealth$are 2(ste', Re aFde Fblia.
54
http://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdfhttp://schizophreniabulletin.oxfordjournals.org/content/35/3/528.full.pdf5/26/2018 06. Bab v - Lampiran
4/34
55
#lson, -., 1>>*, Clini$al Phar'a$olog(4 Ma!e #i!i$ulousl( 2i'+le, &he
3Gra$)ill =duation.
ersson, .B., 200, The Anato'i$al Thera+euti$ Che'i$al ;&!< Classifi$ation
an! ts Use n The &or!i$ Coutries, /epartement o' ubli )ealth and
!aring ienes, Eppsala Eniersity, Eppsala, eden.
/=RH usat /ata dan n'ormasi $ erhimpunan Rumah akit eluruh
ndonesia, Pengo.atan 2ki"ofrenia Tak isa 500 Persen/ 200>.
http ://www.pdp ersi.o .id. kses pada tanggal 1> noember 2011.
hoenstadt, ., 200>, 36tra+(ra'i!al 2('+to's,.s hi ( oph re ni a .e m e dt. om,diakses tanggal 1 -uni 2012.
iregar,!. -. ., 200*,Far'asi #u'ah 2akit Teori !an Penera+an, enerbit Buku
edokteran =G!, -akarta, halaman >0$>1.
uhesti, &. 200>. 2ki"ofrenia Paranoi! !an Gangguan Delusional. +akultas
edokteran.Eniersitas &risakti -akarta
&"ay ). & I irana. R. 2002, -.at7-.at Penting. =leD 3edia omputindo
Gramedia, -akarta
&"ay ). &. I irana. R. 2007. -.at7-.at Penting. =disi A. /epartemen
esehatan R.
Aiedebek, heila 8., tahun 200@ Definisi Kesehatan Jiwa, 8andasan
eperaatan esehatan -ia, -akarta.
6.= 3aramis, 1>>4, l'u Ke!okteran Jiwa, halaman 215$2@>, enerbit ir
8angga Eniersity ress.
6)#, 200*, Drug an! Thera+euti$s Co''ittees A Pra$ti$al Gui!e, 6)#,
it(erland, halaman 71$@0.
6)#, 200, 81- Colla.orating Centre For Drug 2tatisti$ Metho!olog(,
?oregian nstitute o' ubli )ealth, #slo.
6)#, 2011, Gui!elines For ATC Classifi$ation an! DDD assign'ent 055,
6)# !ollaborating !entre +or /rug tatistis 3ethodology, #slo.
http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.pdpersi/http://www.schizophrenia.emedtv.com/http://www.schizophrenia.emedtv.com/http://www.schizophrenia.emedtv.com/http://www.pdpersi/http://www.schizophrenia.emedtv.com/5/26/2018 06. Bab v - Lampiran
5/34
5
8ampiran 1. urat ermohonan engambilan /ata
5/26/2018 06. Bab v - Lampiran
6/34
57
8ampiran 2. urat eterangan enelitian
5/26/2018 06. Bab v - Lampiran
7/34
5@
8ampiran *.+ormularium R-/ urakarta &ahun 2011
5/26/2018 06. Bab v - Lampiran
8/34
5>
8ampiran 4. Rekapitulasi 8aporan elayanan Raat nap R-/ urakarta &ahun 2010 dan 2011
REKAPITULASI LAPORAN PELAYANAN RAWAT INAP RSJD SURAKARTA TAUN !"#"?o -enis egiatan -an +eb 3ar pr 3ei -un -ul gust ep #kt ?op /es &otal
1 asien masuk 1>@ 202 252 221 1>5 2*1 1>0 21 222 21@ 224 1>@ 257
2 asien keluar 20@ 1>4 214 240 22@ 21 207 22* 214 211 21@ 1> 25>
J hidupJ mati K 4@ "am 1 1
J mati L 4@ "am 1 1 2
* )ari peraatan 54>7 4*> 521 252 5**@ 5524 5*4* 520 45>5 54>0 51@@ 522> *>22
4 8ama raat 145 424 5540 5@>> 501 50@@ 44* 5@*@ 4@*2 44@ 5157 47@ *01
8# 2>hr 24hr 25hr 24hr 2@hr 21hr 22hr 2hr 22hr 21hr 22hr 24hr 2@@hr
8# &ahun 2010 25 hari
REKAPITULASI LAPORAN PELAYANAN RAWAT INAP RSJD SURAKARTA TAUN !"##?o -enis egiatan -an +eb 3ar pr 3ei -un -ul gust ep #kt ?op /es &otal
1 asien masuk 1@ 1@@ 1@@ 1>5 201 245 242 240 2@5 214 207 21@ 20>
2 asien keluar 202 10 227 1@1 1>2 202 221 2** 242 25 217 201 254*
J hidup
J mati K 4@ "am
J mati L 4@ "am 1 1* )ari peraatan 54*0 4727 52>* 51*4 57>5 *@2 7*17 7477 7@40 7542 *>1 7200 752@
4 8ama raat 22@ *75@ 5>04 4*>0 5207 504 747 >4 7>* 7@* 5> *2* 7*007
8# *0hr 1@hr 25hr 24hr 2hr 27hr 2>hr 2@hr *1hr 2@hr *0hr *1hr *27hr
8# &ahun 2011 27 hari
5>
5/26/2018 06. Bab v - Lampiran
9/34
0
0
8ampiran 5. /ata ntipsikotik asien Raat nap R-/ urakarta &ahun 2010 dan 2011 ;hi(o''enia< +20
DATA ANTIPSIKOTIK PASIEN RAWAT INAP RSJD SURAKARTA TAUN !"#" $S%&i'())enia* F!"
N( Nama (+a, Jan Fe+ -ar Apr -ei Jun Jul Aus, Sep O/, N(p Des T(,al
1 )aloperidol C odomer 5 mg 7*@ 104@ 11** 41@ *27 4* 524 22 174 140 170 545
2 )aloperidol C Gootil 5 mg *51 47 424 *50 07 472 2*0 27 150 *2@ 270 14>@ 5417
* )aloperidol C )aldol 2 mg 10 14 2>4 Risperidone C Risperdal 2 mg 10 147 2 40 @ 45 >0 15 20 22 25 51 70>
5 Risperidone C ?oprenia 2 mg 1551 15@2 2*@4 21@ 172 @77 1505 1@4> 1@24 20*2 17 >@ 2014@
Risperidone C ersidal 2 mg 144 1>1 1212 225* *>1 2041 1*5 141> 142 10 1270 1@>4 121
7 Risperidone C 9o'redal 2 mg 2@>2 2220 27@2 204* *217 247* 2701 24>4 252 2*> 2447 1412 2>57
@ &ri'luopera(in C tela(in 5 mg 4** *** 507 457> *@41 5>11 514 40> 45*2 500> 550> 4744 452
> !hlorproma(ine 100 mg 147 177 255 1>1@ 1@14 12 15 11 10> 170* 15@ 14@7 20@41
10 lo(apin C !lo(aril 100 mg 17 *> 70 7* 5 200 27> @4 14 5 1 *4 12*@
11 lo(apin C !lo(aril 25 mg 114* 4 @* >00 744 125 41@ 50@ 45> 575 755 107 7>50
12 lo(apin C 8u'ten 100 mg 15 *0 *0 *0 *0 15
1* lo(apin C 8u'ten 25 mg 10 70 *0 *0 1>5 15@ 15 0 1>5 100 10 @7*
14 lo(apin C !lorieD 100 mg 457 2 * 15 5> 24 *5 1>
15 lo(apin C !lorieD 25 mg 7 0 7@ 24 21@ @* *5* 1>4 25 R 11>5
1 lo(apin C i(oril 25 mg 50 20 @0 150
17 3aprotiline C 25 mg 2>5 **0 *1@ 10 24 *11 2@5 54> *42 455 45 2*1 40051@ Muetrapine C eraNuel *00 mg 5* 24 1*> 2> 1 @0 7@ 107 @ 1*> 144 100 1040
1> 9otepin C 8odopin 50 mg 11* 240 1>2 4>@ *1@ 2>1 477 5@1 2* 275 41 25 *7>
20 ripipra(ole 10 mg *0 *> 107 *1 *2 2*>
n"eksi
1 !epe(et n"e
2 )aloperidol deanoat ampul 7 > 4 7 @ 4 > @ @ 14 @>
5/26/2018 06. Bab v - Lampiran
10/34
1
1
N( Nama (+a, Jan Fe+ -ar Apr -ei Jun Jul Aus, Sep O/, N(p Des T(,al
* )aloperidol C serenae 5 mgCml 52 52 *5 1*7 * 100 50 5 51 *> 5> 75 77@
4 #la(apine C 9ypreDa 10 mgCml 10 1 1 4 10 40 1 7
5 )aloperidol C lodomer 5 mgCml 111 1>0 10> 117 107 11* 7* 10 10@ 1 157 1 14**
DATA RAWAT INAP ANTIPSIKOTIK PASIEN RAWAT INAP RSJD SURAKARTA TAUN !"## $S%&i'())enia* F!"
N( Nama (+a, Jan Fe+ -ar Apr -ei Jun Jul Aus, Sep O/, N(p Des T(,al
1 )aloperidol C odomer 5 mg 54 21 24* 54 17 22@ 12 10 5@ >0 75 45 112
2 )aloperidol C Gootil 5 mg 174 214 2 442 1@11 24> 4>> 154 1@1> 1245 47 >5* 107*
* )aloperidol C )aldol 2 mg 77 *42 >1 1>4 5 174 2@ 44* 1>@ @0 2>5 541 2777
4 Risperidone C Risperdal 2 mg *4@ >>4 @1* 5*20 *27 *** 4@72 4@5> 420@ 0* 0>2 20* 5@@10
5 Risperidone C ?oprenia 2 mg 204 1@0 41 0 2>7 2* 47 4@1 *@ 1*1 57 20 *402
Risperidone C ersidal 2 mg 252 2*5 205 110 175 *@ 21@ 277 *22 7* 101 10@ 2444
7 Risperidone C 9o'redal 2 mg >@7 542 *74 *10 *11 452 **2 2>@ 541 17* 1@ 27* 471
@ &ri'luopera(in C tela(in 5 mg *2 4@71 47@ 474 515> 5172 444 2@5 >@> *@> 52@ 402 *575>
> !hlorproma(ine 100 mg 1775 15@4 25>4 10>5 *70 @4 1042 1* 121 11@1 1*0 1@* 1>*4>
10 lo(apin C !lo(aril 100 mg 4 4* 1* 25 * 5 4> 51 25 1@4 *74 @0
11 lo(apin C !lo(aril 25 mg 44 17 242 1> *2@ 2@* 245 **> 450 12 22 70 2>50
12 lo(apin C 8u'ten 100 mg 14 * 501* lo(apin C !lorieD 100 mg 5 @ 2@ 1@ 10 10 100 17>
14 lo(apin C !lorieD 25 mg 112 15@ 42 4> @4 451
15 lo(apin C i(oril 25 mg
1 3aprotiline C 25 mg 27 24 10 5 7 > 5 20 5* 5 15
17 Muetrapine C eraNuel *00 mg 147 >* > 4 21@ 17* 271 @ * *7 @0 @ 1**
1@ 9otepin C 8odopin 50 mg 44 @0 50 *@ > 20 114 15> 51 40 >2
5/26/2018 06. Bab v - Lampiran
11/34
2
2
N( Nama (+a, Jan Fe+ -ar Apr -ei Jun Jul Aus, Sep O/, N(p Des T(,al
n"eksi
1 )aloperidol deanoat ampul 2 1 5 1 5 14
2 )aloperidol C serenae 5 mgCml *> 11 5 14 > 1 @ 1 * 15 111
4 )aloperidol C lodomer 5 mgCml 227 72 >0 215 2>0 *07 70 1>5 4>* 255 *** 2* **@*
5/26/2018 06. Bab v - Lampiran
12/34
*
*
8ampiran . /ata enggunaan ntipsikotik asien Raat nap &ahun 2010 dan 2011
DATA PEN00UNAAN ANTIPSIKOTIK PASIEN RAWAT INAP TAUN !"#"
?o Golongan ode &! ?ama obat Bentuk
sediaan /osis terapi-umlah
pemakaian
uantitaspenggunaan
///;mg 0,11
?#5)04 Muetiapine tab 4hari 1:50 mg,100
mg,200 mg,*00 mg1040 *12000 400 7@0 45,*7 1,*7
4 #ther antipsyhotis
henothia(ines ith5 pipera(ine struture
?#5P0@ Risperidone tab 4$1@ mg 7254 1*450@ 5 2>01, 154,>5 47,2
?#5P11 9oteppine tab 75 mg$ *00 mg *74 1@*700 200 >1@,5 5*,4* 1,7
?#5P12 ripipra(ole tab 10$*0 mg 2*> 2*>0 15 15>,** >,2 0,2@
?#5B0 &ri'luopera(ine tab 2$20 mg 4521 22@105 20 11405,25 0*,4@ 20,01
**15,0
5/26/2018 06. Bab v - Lampiran
13/34
4
4
DATA PEN00UNAAN ANTIPSIKOTIK PASIEN RAWAT INAP TAUN !"##
?o Golonganode
&!?ama obat
Bentuk
sediaan/osis terapi
-umlah
pemakaian
uantitas
penggunaan
///
;mg5,5 @ @24@ 15,*4
*
/ia(epines, oDapines,thia(epines, andoDepines
?#5)02 !lo(apine tab maD 00 mg 44>0 *55025 *00 1,1@*.41 2,21
?#5)0* #lan(apine in" 10 mgChr
?#5)04 Muetiapine tab 4hari 1:50 mg,100
mg,200 mg,*00 mg
1** 400@00 400 1002 57,*5
15@>
>,02
1,@7
4 #ther antipsyhotis ?#5P0@ Risperidone tab 4$1@ mg >417 1*@@*4 5 27,7 51,5
?#5P11 9oteppine tab 75$*00 mg >2 *400 200 17* 0,*0
?#5P12 ripipra(ole tab 10$*0 mg
5
henothia(ines ith
pipera(ine struture
?#5B0 &ri'luopera(ine tab 2$20 mg *575> 17@7>5 20 @>*>.75 511,72 1,*
*07,12
5/26/2018 06. Bab v - Lampiran
14/34
5
8ampiran 7. &abel /E >0O &ahun 2010 dan 2011
Ta+el DU 1"2 Ta&un !"#"
?o ode &! ?amaO
penggunaankumulasi
egmen
/E
1 ?#5P0@ Risperidone 47,2 47,2
>0O2 ?#5B0 &ri'luopera(in 20,01 7,21
* ?#5/01 )aloperidol 14,4 @1,7
4 ?#501 !hlorproma(in 12,2 >*,@7
10O
5 ?#5)02 !lo(apin 2,75 >,2
?#5P11 9otepin 1,7 >@,24
7 ?#5)04 Muetiapin 1,*7 >>,1
@ ?#5P12 rippra(ole 0,2@ >>,@>
> ?#5)0* #lan(apin 0,11 100
Ta+el DU 1"2 Ta&un !"##
?o ode &! ?amaO
penggunaankumulasi
egmen
/E
1 ?#5P0@ Risperidone 51,5 51,5
>0O2 ?#5B0 &ri'luopera(in 1,* @,2@
* ?#5/01 )aloperidol 15,*4 @*,2
4 ?#501 !hlorproma(in 12,00 >5,2
10O5 ?#5)02 !lo(apin 2,21 >7,@*
?#5)04 Muetiapin 1,@7 >>,70
7 ?#5P11 9otepin 0,*0 100
5
5/26/2018 06. Bab v - Lampiran
15/34
8ampiran @. &!C/// berdasarkan 6)# Colla.orating Centre tahun 2011
0(l(nan K(3eATC Nama O+a, DDD Ben,u/Se3iaan
P h e no th ia z in e s w ith ?05B01 /i D y r a ( ine 50 mg #
pip e razi n e str u c tu re *0 mg
?05B02 + luph e n a ( ine 10 mg #
1 mg
?05B0* er ph e n a ( ine *0 mg #
7 mg
10 mg
1 mg R
?05B04 r o hlo r p era ( ine 0.1 g R
50 mg
0.1 g #
?05B05 &hiop r op a ( a te 0 mg #
?05B0 & r i' luop era ( ine 20 mg #
@ mg
20 mg R
?05B07 e toph en a ( ine 50 mg #
?05B0@ &hiop r op era ( ine 75 mg #
20 mg
?05B0> B ut a p e ra ( ine 10 mg #
?05B10 era ( ine 0.1 g #0.1 g
P h e no th ia z in e s w ith ?0501 ! hlo r p r om a ( ine 0.* g #
aliphatic sid e-c h a i n 0.1 g
0.* g R
?0502 8 e o m e p r om a ( ine 0.* g #
0.1 g
?050* r om a ( ine 0.1 g
0.* g #
?0504 ep r o m a ( ine 0.1 g #
50 mg
?0505 & r i' lup r om a ( ine 0.1 g #
?050 ! y a m e m a ( ine
0.1 g
?0507 ! hlo r p r o e th a ( ine
P h e no th ia z in e s w ith ?05!01 er i ia ( ine 50 mg #
pip e ridi n e str u c tu re 20 mg
?05!02 &hio r id a ( ine 0.* g #
?05!0* 3 e so r id a ( ine 0.2 g #
0.2 g
?05!04 ipoti a ( ine 10 mg #
5 mg
http://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ABhttp://www.whocc.no/atc_ddd_index/?code=N05AB02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AB10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AAhttp://www.whocc.no/atc_ddd_index/?code=N05AA02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AA07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AChttp://www.whocc.no/atc_ddd_index/?code=N05AC02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AC04&showdescription=yes5/26/2018 06. Bab v - Lampiran
16/34
7
0(l(nan K(3eATC Nama O+a, DDDBen,u/
Se3iaan
Bu ty r op he no ne ?05/01 ) a lop er idol @ mg #d eri va t ives @ mg
*.* mg ?05/02 & r i' lup er idol 2 mg #
?05/0* 3 e lp er one 0.* g #
0.* g
?05/04 3op er one 20 mg
20 mg #
?05/05 ip a mp er one 0.2 g #
?05/0 B r omp er idol 10 mg #
10 mg
*.* mg
?05/07 B e np e r idol 1.5 mg #
?05/0@ / r op er idol
?05/0> + lu a nisone
I n do l e d eri va t ives ?05=01 # D y p er tine 0.12 g #?05=02 3olindone 50 mg #
?05=0* er tindole 1 mg #
?05=04 9 ip r a sidone @0 mg #
40 mg
T h ioxa n th e ne?05+01 + lup e nti D ol mg #
4 mg
?05+02 ! lop e nth iD ol 0.1 g #
0.1 g
?05+0* ! hlo r p r othi D e ne 50 mg
0.* g #
?05+04 &iot iD e ne *0 mg #
?05+05 9 u lo p e nthi D ol *0 mg #
15 mg
*0 mg
Diph e n
y lbut
y lpip e ri ?05G01 + luspi r il e ne 0.7 mg
d in e d eri va t ives ?05G02 imo ( ide 4 mg #?05G0* e n ' lu r idol mg #
Diazepines, ?05)01 8 o D a pine 0.1 g #oxazepines,
thiazepines and
?05)02 ! lo ( a pine 0.* g #
oxepines
?05)0* #l a n ( a pine
0.*
10
10
g
mg
mg
?05)04 Mu e ti a pine
10
0.4
mg
g
#
#
?05)05 s e n a pine 20 mg #
?05)0 ! loti a pine @0 mg #
http://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AEhttp://www.whocc.no/atc_ddd_index/?code=N05AE01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AFhttp://www.whocc.no/atc_ddd_index/?code=N05AF01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AG03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ADhttp://www.whocc.no/atc_ddd_index/?code=N05AD02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AD09&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AEhttp://www.whocc.no/atc_ddd_index/?code=N05AE01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AE04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AFhttp://www.whocc.no/atc_ddd_index/?code=N05AFhttp://www.whocc.no/atc_ddd_index/?code=N05AF01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AF05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AGhttp://www.whocc.no/atc_ddd_index/?code=N05AG02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AG03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AH06&showdescription=yes5/26/2018 06. Bab v - Lampiran
17/34
@
0(l(nan K(3eATC Nama O+a, DDDBen,u/
Se3iaan
@0 mg B e n z a m id es ?05801 ulpi r ide 0.@ g #
0.@ g
?05802 ultop r ide 1.2 g #
?0580* &i a p r ide 0.4 g #0.4 g
?05804 R e mo D ip r ide 0.* g
0.* g #
?05805 misulp r ide 0.4 g #
?0580 A era lip r ide
?05807 8 e osulpi r ide 0.4 g #
it h iu m ?05?01 8 ithium 24 mmol #
!t h e r antips
yc h oti c s ?05P07 r othip e n d y l 0.24 g #0.24 g
?05P0@ R isp er idone 5 mg #
2.7 mg
?05P10 3os a p ra mine
?05P11 9 ot e pine 0.2 g #
?05P12 r ipip ra ( ole 15 mg #
15 mg
?05P1* a lip er idone mg #
2.5 mg ?05P14 lop e r idone
http://www.whocc.no/atc_ddd_index/?code=N05ALhttp://www.whocc.no/atc_ddd_index/?code=N05AL01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ANhttp://www.whocc.no/atc_ddd_index/?code=N05AN01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AXhttp://www.whocc.no/atc_ddd_index/?code=N05AXhttp://www.whocc.no/atc_ddd_index/?code=N05AX07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX11&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX12&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX13&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX14&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ALhttp://www.whocc.no/atc_ddd_index/?code=N05AL01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL02&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL03&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL04&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL05&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL06&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AL07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05ANhttp://www.whocc.no/atc_ddd_index/?code=N05AN01&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AXhttp://www.whocc.no/atc_ddd_index/?code=N05AX07&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX08&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX10&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX11&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX12&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX13&showdescription=yeshttp://www.whocc.no/atc_ddd_index/?code=N05AX14&showdescription=yes5/26/2018 06. Bab v - Lampiran
18/34
>
Lampiran 9. Cara perhitungan obat
Tahun
2010
A. Risperidone
1. Jumlah hari rawat =1719
= Jumlah pasien masuk rawat inap Q LOS
= 1719 Q 19 !
= "#$%%
#. &osis 'ang digunakan di !umah Sakit
!isperidone/!isperdal # mg
= # mg
= 7(9 Q # = 1)1*
!isperidone/+oprenia #
mg !isperidone/,ersidal
# mg
= #(1)* Q #
= 1%*#1 Q #
= #97% Q #
= )(#9%
= ""%)#
= 91#
!isperidone total penggunaan Q = 1").(*
". 0uantitas penggunaan !isperidone = umlah obat Q kekuatan
= 1").(* mg
). &&& untuk !isperidone oral = mg
. &&& real =
kuantitas
penggunaan
&&&
1").(*=
= #%9(1.%
%. &&& / 1(( hr =&&&real
1719
Q 1((
= 1.%)$9
5/26/2018 06. Bab v - Lampiran
19/34
70
&&&/1((hr
Q7. ,ersen =
1((
1.%)$9=
""1$(%Q 1((
= )7.#(
B. Haloperidol
1. Jumlah hari rawat = 1719
= Jumlah pasien masuk rawat inap Q LOS
= 1719 Q 19 !
= "#$%%
#. aloperidol/Lodomer mg = )% Q = #7"#
aloperidol/2o3otil mg = )17 Q = #7(*
aloperidol/aldol # mg = #) Q # = )*
aloperidol/&e4anoat mg = *) Q = )#(
aloperidol/Serena4e mg/ml = 77* Q = "*9(
aloperidol/Lodomer mg/ml = 1)"" Q = 71%
aloperidol total penggunaan Q kekuatan = %.9""mg
". 0uantitas penggunaan aloperidol = umlah obat Q kekuatan
= %.9"" mg
). &&& untuk aloperidol = * mg
. &&& real =kuantitas
penggunaan
&&&
%.9""=
*= *#)1$%"
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
*#)1$%"=
1719Q 1((
= )79$))
5/26/2018 06. Bab v - Lampiran
20/34
71
&&&/1((hr
Q7. ,ersen =
1((
)79$))
""1$(Q 1((=
=
C. CPZ
1. Jumlah hari rawat = 17$19
= Jumlah pasien masuk rawat inap Q LOS= 1719 Q 19 !
= "#$%%
#. &osis 'ang digunakan di !umah Sakit = 1(( mg
C,- 1(( mg total penggunaan = #(.*)1
C,- total penggunaan Q kekuatan = #(.*)1 Q 1((
= #.(*).1((
". 0uantitas penggunaan C,- = umlah obat Q kekuatan
= #.(*).1(( mg
). &&& untuk C,- oral = "(( mg
. &&& real =kuantitas
penggunaan
&&&
#.(*).1((
= "((= %.9)
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
%.9)=17$19
Q 1((
= )()$1"
5/26/2018 06. Bab v - Lampiran
21/34
72
&&&/1((hr
Q7. ,ersen =
1((
)()$1"
""1$(Q 1((=
=
D. TFP
1. Jumlah hari rawat = 1719
= Jumlah pasien masuk rawat inap Q LOS= 1719 Q 19 !
= "#$%%
#. 56, total penggunaan = ).%#1
&osis 'ang digunakan di !umah Sakit = mg
56,/Stelain mg total penggunaan Q kekuatan = ).%#1 Q
= ##*.1(
". 0uantitas penggunaan 56, = umlah obat Q kekuatan
= ##*.1( mg
). &&& untuk 56, = #( mg
. &&& real =kuantitas
penggunaan
&&&
##*.1(=
#(= 11)($#
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
11)($#=
1719Q 1((
= %("$)*
5/26/2018 06. Bab v - Lampiran
22/34
7*
7. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1
th
1((
%("$)*=""1$(%
Q 1((
E. Klozapin
1. Jumlah hari rawat =
1719
= #($(1
= Jumlah pasien masuk rawat inap Q LOS
= 1719 Q 19 !
= "#$%%
0loapin total penggunaan = 119(
0loapin/Cloaril 1(( mg = 1#"* Q 1(( =1#"*((
0loapin/Cloaril # mg = 7)( Q # = 1*%#(
0loapin/Luten 1(( mg = )# Q 1(( = )#((
0loapin/Luten # mg = *7" Q # = #1*#
0loapin/Clorie8 1(( mg = %19 Q 1(( = %19((
0loapin/Clorie8 # mg = 119 Q # = #9*7
0loapin/Sioril # mg = 1( Q # = "7(
0loapin total penggunaan Q kekuatan = )%9.9((
#. 0uantitas penggunaan 0loapin = umlah obat Q kekuatan
= )%9.9(( mg
". &&& untuk 0loapin = "(( mg
). &&& real =kuantitas
penggunaan
&&&
)%9.9((=
"((
5/26/2018 06. Bab v - Lampiran
23/34
= 1%%$""
&&& real
. &&& / 1(( hr =ml hr rawatQ 1((
1%%$"""=
1719Q 1((
= 91$11
%. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
91$11=""1$(%
Q 1((
F. Zotepin
1. Jumlah hari rawat =
1719
= #$7
= Jumlah pasien masuk rawat inap Q LOS
= 1719 Q 19 != "#$%%
-otepin total penggunaan = ".%7)
&osis 'ang digunakan di !umah Sakit = ( mg
-otepin/Lodopin ( mg = "%7)
-otepin total penggunaan Q kekuatan = ".%7) Q ( mg
= 1*".7(( mg
#. 0uantitas penggunaan -otepin = umlah obat Q kekuatan
= 1*".7(( mg
". &&& untuk -otepin = #((
mg
). &&& real =kuantitas
penggunaan
&&&
1*".7((=
#((= 91*$
5/26/2018 06. Bab v - Lampiran
24/34
. &&& / 1(( hr =&&&real
ml hr rawat
Q 1((
91*$=
1719Q 1((
= "$)"
%. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
"$)"=""1$(%
Q 1((
. !uetiapin
1. Jumlah hari rawat =
1719
= 1$%7
= Jumlah pasien masuk rawat inap Q LOS
= 1719Q 19 != "#$%%
uetiapin/Serouel "(( mg total penggunaan= 1.()(
&osis 'ang digunakan di !umah Sakit = "(( mg
uetiapin total penggunaan Q dosis = 1.()( Q "(( mg
= "1#.(((
#. 0uantitas penggunaan uetiapin = umlah obat Q kekuatan
= "1#.((( mg
". &&& untuk uetiapin = )(( mg
). &&& real =kuantitas
penggunaan
&&&
"1#.(((=
)((
= 7*(&&& real
. &&& / 1(( hr =ml hr rawat
Q 1((
5/26/2018 06. Bab v - Lampiran
25/34
7*(=
1719Q 1((
= )$"7
%. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
)$"7=""1$(%
Q 1((
H. Aripiprazole
1. Jumlah hari rawat =
1719
= 1$"7
= Jumlah pasien masuk rawat inap Q LOS
= 1719 Q 19 !
= "#$%%
#. ;ripipraole 1( mg total penggunaan = #"9
&osis 'ang digunakan di !umah Sakit = 1( mg
;ripipraole total penggunaan Q kekuatan = #"9 Q 1( mg
= #."9(
". 0uantitas penggunaan ;ripipraole = umlah obat Q kekuatan
= #."9( mg
). &&& untuk ;ripipraole = 1 mg
. &&& real =
kuantitas
penggunaan&&&
#."9(=
1= 19$""
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
19$""
= 1719 Q 1((
= 9$#%
5/26/2018 06. Bab v - Lampiran
26/34
77
&&&/1((hr
Q7. ,ersen =
1((
9$#%
""1$(Q 1((=
=
". #lanzapine
1. Jumlah hari rawat = 1719
= Jumlah pasien masuk rawat inap Q LOS= 1791 Q 19 !
= "#$%%
#. Olanapine/-'pre8a 1(mg/ml total penggunaan = %7
&osis 'ang digunakan di !umah Sakit = 1( mg
Olanapine total penggunaan Q kekuatan = %7 Q 1( mg
= %7( mg
". 0uantitas penggunaan Olanapine = umlah obat Q kekuatan
= %7( mg
). &&& untuk Olanapine = 1( mg
. &&& real =kuantitas
penggunaan
&&&
%7(=
1(= %7
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
%7=
1719Q 1((
= "$*9
5/26/2018 06. Bab v - Lampiran
27/34
7@
&&&/1((hr
Q7. ,ersen =
1((
"$*9
""1$(Q 1((=
=
TAH$%
2011
A. Risperidone
1. Jumlah hari rawat = 17)7
= Jumlah pasien masuk rawat inap Q LOS
= 17)7 Q #) !
= )1$9#
#. !isperidone total penggunaan = %9.)17
&osis 'ang digunakan di !umah Sakit = # mg
!isperidone/!isperdal # mg = **1( Q # = 117%#(
!isperidone/+oprenia # mg =")(# Q # = %*()
!isperidone/,ersidal #mg =#))) Q # = )***
!isperidone /-oredal #mg = )7%1 Q # = 9##
5/26/2018 06. Bab v - Lampiran
28/34
7>
!isperidone total penggunaan Q kekuatan = 1"*.*") mg
". 0uantitas penggunaan !isperidone = umlah obat Q kekuatan
= 1"*.*") mg
). &&& untuk !isperidone oral = mg
. &&& real =kuantitas
penggunaan
&&&
1"*.*")=
= #7.7%
%. &&& / 1(( hr =&&&real
17)7
Q 1((
= 1.*9
7. ,ersen penggunaan = &&&/1((hr Qml &&&/1((hr selama 1
th
1((
1$*9="(7%$1#
Q 1((
= 1$%
B. Haloperidol
1. Jumlah hari rawat = 17)7
= Jumlah pasien masuk rawat inap Q LOS
= 17)7 Q #) !
= )1$9#
#. aloperidol/Lodomer mg =11%# Q = *1(
aloperidol/2o3otil mg = 1(%7" Q =
aloperidol/aldol # mg = #777 Q # = )
aloperidol/&e4anoat amp (mg/ml
aloperido/Serena4e (mg/ml
= 1) Q (
= 111 Q
=7((
=
5/26/2018 06. Bab v - Lampiran
29/34
aloperidol total penggunaan Q kekuatan = %.9*)
". 0uantitas penggunaan aloperidol = umlah obat Q kekuatan
= %.9*) mg
). &&& untuk aloperidol oral = * mg
. &&& real =kuantitas
penggunaan
&&&
%.9*)=
*= *#)*
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
*#)*=
17)7Q 1((
= )7#$1#
7. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
)7#$1#="(7%$1#
Q 1((
C. CPZ
1. Jumlah hari rawat =
17)7
= 1$")
= Jumlah pasien masuk rawat inap Q LOS
= 17)7 Q #) !
= )1$9#
#. C,- total penggunaan = 19")9
&osis 'ang digunakan di !umah Sakit = 1(( mg
C,-1(( mg total penggunaan Q kekuatan= 19")9 Q 1((
= 19").9((
". 0uantitas penggunaan C,- = umlah obat Q kekuatan
5/26/2018 06. Bab v - Lampiran
30/34
= 1.9").9(( mg
). &&& untuk C,- oral = "(( mg
. &&& real =kuantitas
penggunaan
&&&
1.93).9((=
"((= %.))9.%%%
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
%.))9.%%%=
17)7Q 1((
= "%9$1*
7. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1
th
1((
"%9$1*="(7%$1#
Q 1((
= 1#$((
D. TFP
1. Jumlah hari rawat = 17)7
= Jumlah pasien masuk rawat inap Q LOS
= 17)7 Q #) !
= )1$9#
#. 56, total penggunaan = ".79
&osis 'ang digunakan di !umah Sakit = mg
56, mg total penggunaan Q kekuatan = ".79 Q
= 17*.79
". 0uantitas penggunaan 56, = umlah obat Q kekuatan
5/26/2018 06. Bab v - Lampiran
31/34
@2
= 17*.79
0loapin/Cloaril 1(( mg
0loapin/Cloaril # mg
= *%( Q 1(( = *%(((
= #9( Q # = 7"7(
0loapin/Luten 1(( mg = ( Q 1(( = (((
0loapin/Clorie8 1(( mg = 179 Q 1(( = 179((
0loapin/Clorie8 # mg
0loapin total penggunaan Q kekuatan
= )1 Q # = 11#7
=
". 0uantitas penggunaan 0loapin = umlah obat Q kekuat
). &&& untuk 56, = #( mg
. &&& real =kuantitas
penggunaan
&&&
17*.79=
#(= *9"9.7
%. &&& / 1(( hr = &&&real
ml hr rawat
Q 1((
*9"9$7=
1)7)7Q 1((
= 11$7#
7. ,ersen penggunaan =&&&/1((hr
Q
ml &&&/1((hr selama 1th
1((
511 ,72="(7%$1#
Q 1((
E. Klozapin
1. Jumlah hari rawat =
17)7
= 1%$%"
= Jumlah pasien masuk rawat inap Q LOS
= 17)7 Q #) !
= )1$9#
#. 0loapin total penggunaan = ))9(
an
5/26/2018 06. Bab v - Lampiran
32/34
@*
= "(# mg
). &&& untuk 0loapin = "(( mg
. &&& real =kuantitas
penggunaan
&&&
"(#=
"((= 11*"$)1
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
11*"$)1=
17)7Q 1((
= %7$7"
7. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
%7$7"
="(7%$1# Q 1((
F. Zotepin
1. Jumlah hari rawat =
17)7
= #$#1
0,!< = Jumlah pasien masuk rawat inapQ LOS
= 17)7 Q #) !
= )1$9#
#. -otepin total penggunaan = %9#
&osis 'ang digunakan di !umah Sakit = ( mg
-otepin ( mg total penggunaan Q kekuatan = %9# Q ( mg
= ")%(( mg
". 0uantitas penggunaan -otepin = umlah obat Q kekuatan
= ")%(( mg
5/26/2018 06. Bab v - Lampiran
33/34
). &&& untuk -otepin = #(( mg
. &&& real = kuantitaspenggunaan
&&&
")%((=
#((= 17"
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
17"=
17)7Q 1((
= 9$(#
7. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
9$(#="(7%$1#
Q 1((
. !uetiapin
1. Jumlah hari rawat =
17)7
= ($"(
0,!< = Jumlah pasien masuk rawat inap Q LOS
= 17)7 Q #) !
= )1$9#
#. uetiapin "(( mg total penggunaan = 1.""%
&osis 'ang digunakan di !umah Sakit = "(( mg
uetiapin total penggunaan Q kekuatan = 1.""% Q "(( mg
= )((.*((
". 0uantitas penggunaan uetiapin = umlah obat Q kekuatan
= )((.*(( mg
). &&& untuk uetiapin = )(( mg
5/26/2018 06. Bab v - Lampiran
34/34
. &&& real =kuantitas
penggunaan
&&&
)((.*((=
)((= 1((#
&&& real%. &&& / 1(( hr =
ml hr rawatQ 1((
1((#=
17)7
Q 1((
= 7$"
7. ,ersen penggunaan =&&&/1((hr
Qml &&&/1((hr selama 1 th
1((
7$"="(7%$1#
Q 1((
= 1$*7
Top Related